 Approximately 1000 elderly male and female subjects, aged 65 years or older, will be randomized in a 1:1:1:1 ratio to 1of 4 parallel treatment groups such that 500 subjects receive Quadrivalent VLP Vaccine 250 each for the 30 μgstrain and 60 μgstrain groups, 250 subjects receive FluLaval Tetra 15 μgstrain and 250 subjects receive Fluzone HD 60 μgstrain. Subjects in each group will be stratified into 2 age strata: 65 to 74 years and 75 years old and older, where 70 of subjects will be enrolled into the 65 to 74 years old age group and 30 into the 75 years old or older group. 